enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Empagliflozin - Wikipedia

   en.wikipedia.org/wiki/Empagliflozin

   The risk of empagliflozin-associated euglycemic diabetic ketoacidosis may be higher in the setting of illness, dehydration, surgery, and/or alcohol consumption. [38] It is also seen in type 1 diabetes who take empagliflozin, which notably is an unapproved or "off-label" use of the medication. [39]

3. SGLT2 inhibitor - Wikipedia

   en.wikipedia.org/wiki/SGLT2_inhibitor

   Empagliflozin, approved in the United States in August 2014, under the brand name Jardiance by Boehringer Ingelheim. [30] Of the gliflozins, empagliflozin and tofogliflozin have the highest specificity for SGLT2 inhibition. [1] This oral medicine for type 2 diabetes has been shown to reduce the risk of cardiovascular death. [31]

4. Empagliflozin/metformin - Wikipedia

   en.wikipedia.org/wiki/Empagliflozin/metformin

   Empagliflozin/metformin was approved for use in the European Union in May 2015. [6] Empagliflozin/metformin was approved for use in the United States in August 2015. [7] [12] The extended release version was approved for use in the United States in December 2016. [13] [14] Empagliflozin/metformin was approved for use in Australia in May 2020. [2]

5. Type 2 diabetes: Roche says its weekly drug works ... - AOL

   www.aol.com/2009/12/02/type-2-diabetes-roche...

   The $5 billion U.S. diabetes drug market just got a little more competitive. Swiss drugmaker Roche (RHHBY) said Wednesday an experimental medicine in late-stage development works better in ...

6. Serious Ozempic Side Effects, Confirmed: Here’s What to Know

   www.aol.com/lifestyle/serious-ozempic-side...

   The study, which was published in Nature Medicine on January 20, analyzed data from more than 2 million people with diabetes who took GLP-1 receptor agonist medications like Ozempic and Wegovy.

7. FDA Rejects Eli Lilly's Diabetes Drug Empagliflozin - AOL

   www.aol.com/news/2014-03-05-fda-rejects-eli...

   Eli Lilly and Boehringer Ingelheim Pharmaceuticals said today that the Food and Drug Administration rejected empagliflozin, the most recent drug to come out of the companies' diabetes partnership.